Phase l/II Study of Ruxolitinib for Acute Leukemia
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib
that can be given to patients with acute leukemia and to learn if the study drug can help
control the disease. The safety of the drug will also be studied.